Kbio Labs케이바이오랩스
038530 · KOSDAQ · ₩038530 · 케이바이오랩스
₩3,105▲ ₩40 (1.31%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 13.8% | 14.5% | 15.4% | 13.5% | 14.9% | 22.2% |
| Operating margin | 2.2% | 1.7% | 1.0% | −2.1% | −0.5% | −54.8% |
| Net margin | −22.0% | −3.7% | −8.9% | −46.4% | −22.8% | −223.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −22.4% | +14.1% | +180.0% | −18.8% | +285.8% | — |
| Operating income growth | −1.7% | +91.9% | +241.3% | −268.0% | +96.8% | — |
| Net income growth | −365.1% | +52.9% | +46.4% | −65.4% | +60.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −31.9% | −5.8% | −11.4% | −19.5% | −11.8% | −30.9% |
| Return on assets | −43.2% | −4.3% | −7.7% | −11.2% | −9.0% | −22.3% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 17.7% | 16.2% | 9.4% | 11.4% | 23.5% | 38.7% |
| Net debt to equity | −22.8% | −49.1% | −42.3% | −43.8% | −44.5% | −38.0% |
| Current ratio | 607.5% | 520.0% | 735.2% | 610.7% | 326.5% | 266.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kbio Labs / 케이바이오랩스 / 038530 / KRX:038530
Source: KRX statistical information